NovoCure Ltd — Director's Dealing 2022

Jun 10, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NovoCure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2022-06-08

Reporting Person: Madden Martin J. (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-06-08	Options to Buy Ordinary Shares	$77.25	A	8700	Acquired	2032-06-08	Ordinary Shares (8700.0)	Direct

Footnotes

F1: Options to buy 8,700 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2023 annual general meeting of shareholders.